The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics
Open accessAbstract
Tumor necrosis factor alpha (TNF-α) was initially recognized as a factor that causes the necrosis of tumors, but it has been recently identified to have additional important functions as a pathological component of autoimmune diseases. TNF-α binds to two different receptors, which initiate signal transduction pathways. These pathways lead to various cellular responses, including cell survival, differentiation, and proliferation. However, the inappropriate or excessive activation of TNF-α signaling is associated with chronic inflammation and can eventually lead to the development of pathological complications such as autoimmune diseases. Understanding of the TNF-α signaling mechanism has been expanded and applied for the treatment of immune diseases, which has resulted in the development of effective therapeutic tools, including TNF-α inhibitors. Currently, clinically approved TNF-α inhibitors have shown noticeable potency in a variety of autoimmune diseases, and novel TNF-α signaling inhibitors are being clinically evaluated. In this review, we briefly introduce the impact of TNF-α signaling on autoimmune diseases and its inhibitors, which are used as therapeutic agents against autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: The treatment of rheumatoid arthritis
Simon, L. S. (2004) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2004.04.005 · Cited by 19
RetractedA metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
Boehncke, W.-H., & Schön, M. P. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61909-7 · Cited by 2,542
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
Cho, Y., Challa, S., Moquin, D., Genga, R., Ray, T. D., Guildford, M., & Chan, F. K.-M. (2009) · Cell · doi:10.1016/j.cell.2009.05.037 · Cited by 2,435 · cited 1×
“Complex IIc activates the mixed lineage kinase domain-like protein (MLKL) via RIPK3-mediated phosphorylation, which induces necroptosis and inflammation (Figure 1) [13,20].”
BackgroundCytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E. H. S., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,249
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Necroptosis and its role in inflammation
Pasparakis, M., & Vandenabeele, P. (2015) · Nature · doi:10.1038/nature14191 · Cited by 2,148
Inflammatory bowel disease: cause and immunobiology
Baumgart, D. C., & Carding, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60750-8 · Cited by 2,147
TNF-mediated inflammatory disease
Bradley, Jr. (2008) · The Journal of Pathology · doi:10.1002/path.2287 · Cited by 2,094 · cited 1×
“It has been identified as a major regulator of inflammatory responses and is known to be involved in the pathogenesis of some inflammatory and autoimmune diseases [1].”
Background
Research works printed but not linked: 14
- Morita, 2001, Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: Molecular and functional analysis, Arthritis Rheum., 44, 2819, 10.1002/1529-0131(200112)44:12<2819::AID-ART469>3.0.CO;2-2 · doi:10.1002/1529-0131(200112)44:12<2819::aid-art469>3.0.co;2-2
- Hasan, 2007, Angiotensin-Converting enzyme gene polymorphism in patients with psoriatic arthritis, Rheumatol. Int., 27, 1119, 10.1007/s00296-007-0349-y · doi:10.1007/s00296-007-0349-y
- Ringheanu, 2004, Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn’s disease, Inflamm. Bowel Dis., 10, 801, 10.1097/00054725-200411000-00015 · doi:10.1097/00054725-200411000-00015
- Rosenbaum, 2019, New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review, Semin. Arthritis Rheum., 49, 438, 10.1016/j.semarthrit.2019.06.004 · DOI
- Fearon, 2018, The pathogenic role of dendritic cells in non-infectious anterior uveitis, Exp. Eye Res., 173, 121, 10.1016/j.exer.2018.05.008 · doi:10.1016/j.exer.2018.05.008
- Reddy, S.P., Shah, V.V., Lin, E.J., and Wu, J.J. (2016). Therapy for Severe Psoriasis, Elsevier.
- Tan, 2007, Mechanisms of action of etanercept in psoriasis, J. Investig. Dermatol. Symp. Proc., 12, 38, 10.1038/sj.jidsymp.5650037 · doi:10.1038/sj.jidsymp.5650037
- Brambilla, A., and Simonini, G. (2016). Handbook of Systemic Autoimmune Diseases, Elsevier.
- LaMattina, 2017, Adalimumab for the treatment of uveitis, Expert Rev. Clin. Immunol., 13, 181, 10.1080/1744666X.2017.1288097 · doi:10.1080/1744666x.2017.1288097
- Rosa, 2016, An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: Place in therapy, Open Access Rheumatol., 8, 37
- Desai, 2012, Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis, Ann. Pharmacother., 46, 1491, 10.1345/aph.1R203 · DOI
- Shealy, 2007, Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for human TNFα, Ann. Rheum. Dis., 66, 151
- Mazumdar, 2009, Golimumab, mAbs, 1, 422, 10.4161/mabs.1.5.9286 · doi:10.4161/mabs.1.5.9286
- Dahmus, 2020, Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy, Clin. Exp. Gastroenter., 13, 339, 10.2147/CEG.S237646 · doi:10.2147/ceg.s237646
Cited by
Bifidobacterium Longum: Protection against Inflammatory Bowel Disease
Yao, S., Zhao, Z., Wang, W., & Liu, X. (2021) · Journal of Immunology Research · doi:10.1155/2021/8030297 · Cited by 255
Natarajan, N., Batts, S., & Stankovic, K. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062347 · Cited by 254
Galbraith, M. D., Rachubinski, A. L., Smith, K. P., Araya, P., Waugh, K. A., Enriquez-Estrada, B., Worek, K., Granrath, R. E., Kinning, K. T., Paul Eduthan, N., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg6218 · Cited by 88
New Insights into Adipokines in Gestational Diabetes Mellitus
Valencia-Ortega, J., González-Reynoso, R., Ramos-Martínez, E. G., Ferreira-Hermosillo, A., Peña-Cano, M. I., Morales-Ávila, E., & Saucedo, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116279 · Cited by 39
Yu, W.-R., Jhang, J.-F., Jiang, Y.-H., & Kuo, H.-C. (2024) · Biomedicines · doi:10.3390/biomedicines12092051 · Cited by 39
Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02812-3 · Cited by 40
Saha, D., Dutta, P., & Chakraborty, A. (2025) · Immuno · doi:10.3390/immuno5040045 · Cited by 3
Single-molecule imaging of transcription dynamics, RNA localization and fate in human T cells
Lattanzio, M. V., Šoštarić, N., Kanagasabesan, N., Popović, B., Bradarić, A., Wardak, L., Guislain, A., Savakis, P., Tutucci, E., & Wolkers, M. C. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00592-0 · Cited by 3
Phan, A., Joshi, P., Kadelka, C., & Friedberg, I. (2025) · Database · doi:10.1093/database/baaf036 · Cited by 2
“We controlled the family-wise error rate at 0.05 using the Bonferroni multi hypothesis correction (47, 48).”
InfluentialMacrophage INSIG1 deficiency drives psoriasiform dermatitis via the SREBP2-STAT1 axis
Li, X., Zang, Y., Li, X., Sheng, T., Liu, S., Chen, L., Xu, X., Wang, L., Long, R., Zhang, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73278-8 · Cited by 1
Metadata
- Authors
- Jang, D.-I., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., & Yang, S.-H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-03-08
- Volume
- 22
- Issue
- 5
- Pages
- 2719
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3134454558
- Cited by
- 1,694
- References
- 83
- FWCI
- 141.32
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Dongguk University Research Fund of 2019 (S-2019-G0001-00009)
- Cooperative Research Program for Agriculture Science & Technology Development of Rural Development Administration in Republic of Korea (Project No. PJ014297)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.